Takeda aligns with leading rare disease group for calls to action around health equity diagnoses
Takeda isn’t as well-known in rare disease as some other pharma companies, but it’s aiming to take a broader leadership role. Its recent partnership with the leading rare disease advocacy group, the National Organization for Rare Disorders (NORD), is advancing that ambition in part with a new report focused on health inequities in diagnosing rare diseases — and a list of recommendations to address it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
